Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation.
Anticoagulation
Atrial fibrillation
Drug-drug interactions
Rifampin
Tuberculosis
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
04 04 2023
04 04 2023
Historique:
received:
29
08
2022
accepted:
29
03
2023
medline:
6
4
2023
entrez:
4
4
2023
pubmed:
5
4
2023
Statut:
epublish
Résumé
Evidence and guidelines for Non-vitamin K antagonist oral anticoagulants (NOACs) use when prescribing concurrent rifampin for tuberculosis treatment in patients with non-valvular atrial fibrillation (NVAF) are limited. Using the Korean National Health Insurance Service database from January 2009 to December 2018, we performed a population-based retrospective cohort study to assess the net adverse clinical events (NACE), a composite of ischemic stroke or systemic embolism and major bleeding, of NOACs compared with warfarin among NVAF patients taking concurrent rifampin administration for tuberculosis treatment. After a propensity matching score (PSM) analysis, Cox proportional hazards regression was performed in matched cohorts to investigate the clinical outcomes. Of the 735 consecutive patients selected, 465 (63.3%) received warfarin and 270 (36.7%) received NOACs. Among 254 pairs of patients after PSM, the crude incidence rate of NACE was 25.6 in NOAC group and 32.8 per 100 person-years in warfarin group. There was no significant difference between NOAC and warfarin use in NACE (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.48-1.14; P = 0.172). Major bleeding was the main driver of NACE, and NOAC use was associated with a statistically significantly lower risk of major bleeding than that with warfarin use (HR, 0.63; 95% CI, 0.40-1.00; P = 0.0499). In our population-based study, there was no statically significant difference in the occurrence of NACE between NOAC and warfarin use. NOAC use may be associated with a lower risk of major bleeding than that with warfarin use.
Sections du résumé
BACKGROUND
Evidence and guidelines for Non-vitamin K antagonist oral anticoagulants (NOACs) use when prescribing concurrent rifampin for tuberculosis treatment in patients with non-valvular atrial fibrillation (NVAF) are limited.
METHODS
Using the Korean National Health Insurance Service database from January 2009 to December 2018, we performed a population-based retrospective cohort study to assess the net adverse clinical events (NACE), a composite of ischemic stroke or systemic embolism and major bleeding, of NOACs compared with warfarin among NVAF patients taking concurrent rifampin administration for tuberculosis treatment. After a propensity matching score (PSM) analysis, Cox proportional hazards regression was performed in matched cohorts to investigate the clinical outcomes.
RESULTS
Of the 735 consecutive patients selected, 465 (63.3%) received warfarin and 270 (36.7%) received NOACs. Among 254 pairs of patients after PSM, the crude incidence rate of NACE was 25.6 in NOAC group and 32.8 per 100 person-years in warfarin group. There was no significant difference between NOAC and warfarin use in NACE (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.48-1.14; P = 0.172). Major bleeding was the main driver of NACE, and NOAC use was associated with a statistically significantly lower risk of major bleeding than that with warfarin use (HR, 0.63; 95% CI, 0.40-1.00; P = 0.0499).
CONCLUSIONS
In our population-based study, there was no statically significant difference in the occurrence of NACE between NOAC and warfarin use. NOAC use may be associated with a lower risk of major bleeding than that with warfarin use.
Identifiants
pubmed: 37016321
doi: 10.1186/s12872-023-03212-z
pii: 10.1186/s12872-023-03212-z
pmc: PMC10074893
doi:
Substances chimiques
Anticoagulants
0
Warfarin
5Q7ZVV76EI
Rifampin
VJT6J7R4TR
Rivaroxaban
9NDF7JZ4M3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
182Informations de copyright
© 2023. The Author(s).
Références
BMC Pharmacol Toxicol. 2013 May 04;14:27
pubmed: 23641931
Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27
pubmed: 26749408
Heart Rhythm. 2020 Dec;17(12):2102-2110
pubmed: 32702416
Cardiovasc Hematol Disord Drug Targets. 2017;17(2):105-110
pubmed: 28676032
Eur J Clin Pharmacol. 2021 Mar;77(3):409-419
pubmed: 33029651
Circulation. 2013 Feb 5;127(5):634-40
pubmed: 23271794
Stroke. 2010 Feb;41(2):244-9
pubmed: 20035070
Circulation. 2018 Oct 30;138(18):1963-1973
pubmed: 29967197
Drugs R D. 2013 Sep;13(3):191-7
pubmed: 23982688
Basic Clin Pharmacol Toxicol. 2021 Mar;128(3):440-454
pubmed: 33037766
Am J Cardiol. 2020 May 1;125(9):1332-1338
pubmed: 32098658
J Am Heart Assoc. 2016 Feb 23;5(2):
pubmed: 26908401
Infect Chemother. 2019 Jun;51(2):142-149
pubmed: 31270993
J Am Coll Cardiol. 2020 Mar 24;75(11):1341-1350
pubmed: 32192661
Korean Circ J. 2020 Sep;50(9):754-772
pubmed: 32725984
Sci Rep. 2020 Feb 4;10(1):1801
pubmed: 32019993
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Circ Arrhythm Electrophysiol. 2022 Jun;15(6):e007956
pubmed: 35622425
JAMA Intern Med. 2020 Aug 1;180(8):1052-1060
pubmed: 32511684
JAMA. 2017 Oct 3;318(13):1250-1259
pubmed: 28973247
BMJ. 2016 Jun 15;353:i2868
pubmed: 27306620
Korean Circ J. 2020 Mar;50(3):267-277
pubmed: 32100483
Cardiovasc Drugs Ther. 2019 Oct;33(5):615-623
pubmed: 31520256
Clin Infect Dis. 2017 Jan 15;64(2):e1-e33
pubmed: 27932390
Springerplus. 2016 Jan 04;5:8
pubmed: 26759747
Case Rep Med. 2019 Jan 23;2019:4917856
pubmed: 30809261
Cardiol Rev. 2016 Sep-Oct;24(5):218-23
pubmed: 26274538
Br J Clin Pharmacol. 2012 Sep;74(3):490-500
pubmed: 22348256
Clin Drug Investig. 2015 Jul;35(7):447-53
pubmed: 26068927
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
Drugs. 2019 Oct;79(15):1625-1634
pubmed: 31440911
J Am Coll Cardiol. 2021 Mar 9;77(9):1197-1207
pubmed: 33663737
Eur Heart J. 2018 Apr 21;39(16):1330-1393
pubmed: 29562325
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Circulation. 2019 Apr 30;139(18):2170-2185
pubmed: 31034291